# Innovex International, Inc.: financial statements, quarterly

INVX · NYSE · CIK 1042893 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/invx.md) · [Financials](/companies/invx/financials.md) · [Filings](/companies/invx/filings.md) · [Insiders](/companies/invx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/invx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [139](/filings/0000950170-24-124037.md) | [133 d](/filings/0001193125-26-067228.md) | [128](/filings/0000950170-25-065770.md) | [130](/filings/0000950170-25-104162.md) | [152](/filings/0001193125-25-265003.md) | [251 d](/filings/0001193125-26-067228.md) | [240](/filings/0001193125-26-206528.md) | [224](/filings/0001193125-26-332959.md) | [240](/filings/0001193125-25-265003.md) | [274 d](/filings/0001193125-26-067228.md) | [239](/filings/0001193125-26-206528.md) | [245](/filings/0001193125-26-332959.md) |
| Cost of revenue | $m | [89.2](/filings/0000950170-24-124037.md) | [84.7 d](/filings/0001193125-26-067228.md) | [78.9](/filings/0000950170-25-065770.md) | [84.3](/filings/0000950170-25-104162.md) | [99.1](/filings/0001193125-25-265003.md) | [166 d](/filings/0001193125-26-067228.md) | [164](/filings/0001193125-26-206528.md) | [153](/filings/0001193125-26-332959.md) | [164](/filings/0001193125-25-265003.md) | [194 d](/filings/0001193125-26-067228.md) | [155](/filings/0001193125-26-206528.md) | [161](/filings/0001193125-26-332959.md) |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [19.2](/filings/0000950170-24-124037.md) | [18.7 d](/filings/0001193125-26-067228.md) | [21.3](/filings/0000950170-25-065770.md) | [18.6](/filings/0000950170-25-104162.md) | [38.0](/filings/0001193125-25-265003.md) | [38.3 d](/filings/0001193125-26-067228.md) | [32.3](/filings/0001193125-26-206528.md) | [28.8](/filings/0001193125-26-332959.md) | [35.6](/filings/0001193125-25-265003.md) | [32.0 d](/filings/0001193125-26-067228.md) | [41.7](/filings/0001193125-26-206528.md) | [39.1](/filings/0001193125-26-332959.md) |
| Operating income | $m | [24.0](/filings/0000950170-24-124037.md) | [23.3 d](/filings/0001193125-26-067228.md) | [22.3](/filings/0000950170-25-065770.md) | [13.1](/filings/0000950170-25-104162.md) | [(13.2)](/filings/0001193125-25-265003.md) | [26.9 d](/filings/0001193125-26-067228.md) | [21.9](/filings/0001193125-26-206528.md) | [22.7](/filings/0001193125-26-332959.md) | [62.3](/filings/0001193125-25-265003.md) | [25.8 d](/filings/0001193125-26-067228.md) | [(21.8)](/filings/0001193125-26-206528.md) | [33.8](/filings/0001193125-26-332959.md) |
| Interest expense | $m | [1.5](/filings/0000950170-24-124037.md) | [0.8 d](/filings/0001193125-26-067228.md) | [0.7](/filings/0000950170-25-065770.md) | [0.6](/filings/0000950170-25-104162.md) | [0.7](/filings/0001193125-25-265003.md) | [0.4 d](/filings/0001193125-26-067228.md) | [0.7](/filings/0001193125-26-206528.md) | [0.6](/filings/0001193125-26-332959.md) | [0.7](/filings/0001193125-25-265003.md) | [0.7 d](/filings/0001193125-26-067228.md) | [(0.4)](/filings/0001193125-26-206528.md) | [(0.7)](/filings/0001193125-26-332959.md) |
| Income tax | $m | [7.9](/filings/0000950170-24-124037.md) | [5.0 d](/filings/0001193125-26-067228.md) | [5.1](/filings/0000950170-25-065770.md) | [4.3](/filings/0000950170-25-104162.md) | [(2.6)](/filings/0001193125-25-265003.md) | [(4.4) d](/filings/0001193125-26-067228.md) | [6.6](/filings/0001193125-26-206528.md) | [6.9](/filings/0001193125-26-332959.md) | [18.7](/filings/0001193125-25-265003.md) | [13.0 d](/filings/0001193125-26-067228.md) | [(4.9)](/filings/0001193125-26-206528.md) | [10.4](/filings/0001193125-26-332959.md) |
| Net income | $m | [15.4](/filings/0000950170-24-124037.md) | [18.4 d](/filings/0001193125-26-067228.md) | [16.4](/filings/0000950170-25-065770.md) | [9.5](/filings/0000950170-25-104162.md) | [82.6](/filings/0001193125-25-265003.md) | [31.8 d](/filings/0001193125-26-067228.md) | [14.8](/filings/0001193125-26-206528.md) | [15.3](/filings/0001193125-26-332959.md) | [39.2](/filings/0001193125-25-265003.md) | [14.0 d](/filings/0001193125-26-067228.md) | [(16.7)](/filings/0001193125-26-206528.md) | [25.0](/filings/0001193125-26-332959.md) |
| Diluted EPS | $ per share | [0.48](/filings/0000950170-24-124037.md) | not reported | [0.51](/filings/0000950170-25-065770.md) | [0.30](/filings/0000950170-25-104162.md) | [1.99](/filings/0001193125-25-265003.md) | not reported | [0.21](/filings/0001193125-26-206528.md) | [0.22](/filings/0001193125-26-332959.md) | [0.57](/filings/0001193125-25-265003.md) | not reported | [(0.24)](/filings/0001193125-26-206528.md) | [0.36](/filings/0001193125-26-332959.md) |
| Basic EPS | $ per share | [0.50](/filings/0000950170-24-124037.md) | not reported | [0.53](/filings/0000950170-25-065770.md) | [0.31](/filings/0000950170-25-104162.md) | [2.03](/filings/0001193125-25-265003.md) | not reported | [0.21](/filings/0001193125-26-206528.md) | [0.22](/filings/0001193125-26-332959.md) | [0.57](/filings/0001193125-25-265003.md) | not reported | [(0.24)](/filings/0001193125-26-206528.md) | [0.36](/filings/0001193125-26-332959.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [181](/filings/0000950170-23-057180.md) | [187](/filings/0000950170-24-092740.md) | [198](/filings/0000950170-24-082111.md) | [186](/filings/0000950170-24-092740.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current assets | $m | [709](/filings/0000950170-23-057180.md) | [288](/filings/0000950170-25-031003.md) | [715](/filings/0000950170-24-082111.md) | [708](/filings/0000950170-24-092740.md) | [677](/filings/0000950170-24-124037.md) | [641](/filings/0001193125-26-067228.md) | [633](/filings/0000950170-25-065770.md) | [670](/filings/0000950170-25-104162.md) | [710](/filings/0001193125-25-265003.md) | [728](/filings/0001193125-26-332959.md) | [753](/filings/0001193125-26-206528.md) | [789](/filings/0001193125-26-332959.md) |
| Total assets | $m | [1,008](/filings/0000950170-23-057180.md) | [475](/filings/0000950170-25-031003.md) | [1,021](/filings/0000950170-24-082111.md) | [1,008](/filings/0000950170-24-092740.md) | [1,133](/filings/0000950170-24-124037.md) | [1,197](/filings/0001193125-26-067228.md) | [1,196](/filings/0000950170-25-065770.md) | [1,227](/filings/0000950170-25-104162.md) | [1,254](/filings/0001193125-25-265003.md) | [1,268](/filings/0001193125-26-332959.md) | [1,288](/filings/0001193125-26-206528.md) | [1,328](/filings/0001193125-26-332959.md) |
| Current liabilities | $m | [107](/filings/0000950170-23-057180.md) | [78.6](/filings/0000950170-25-031003.md) | [134](/filings/0000950170-24-082111.md) | [126](/filings/0000950170-24-092740.md) | [175](/filings/0000950170-24-124037.md) | [163](/filings/0001193125-26-067228.md) | [146](/filings/0000950170-25-065770.md) | [146](/filings/0000950170-25-104162.md) | [149](/filings/0001193125-25-265003.md) | [148](/filings/0001193125-26-332959.md) | [148](/filings/0001193125-26-206528.md) | [158](/filings/0001193125-26-332959.md) |
| Total liabilities | $m | [137](/filings/0000950170-23-057180.md) | [146](/filings/0000950170-25-031003.md) | [164](/filings/0000950170-24-082111.md) | [156](/filings/0000950170-24-092740.md) | [228](/filings/0000950170-24-124037.md) | [239](/filings/0001193125-26-067228.md) | [218](/filings/0000950170-25-065770.md) | [232](/filings/0000950170-25-104162.md) | [215](/filings/0001193125-25-265003.md) | [211](/filings/0001193125-26-332959.md) | [257](/filings/0001193125-26-206528.md) | [269](/filings/0001193125-26-332959.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | [25.4](/filings/0000950170-25-031003.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [308](/filings/0000950170-24-124037.md) | [329](/filings/0001193125-26-067228.md) | [344](/filings/0000950170-25-104162.md) | [352](/filings/0001193125-25-265003.md) | [904](/filings/0001193125-25-265003.md) | [958](/filings/0001193125-26-332959.md) | [978](/filings/0001193125-26-332959.md) | [996](/filings/0001193125-26-332959.md) | [1,039](/filings/0001193125-25-265003.md) | [1,058](/filings/0001193125-26-332959.md) | [1,031](/filings/0001193125-26-332959.md) | [1,058](/filings/0001193125-26-332959.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [96.1 d](/filings/0000950170-24-124037.md) | [21.4 d](/filings/0001193125-26-067228.md) | [12.6](/filings/0000950170-25-065770.md) | [22.8 d](/filings/0000950170-25-104162.md) | [21.7 d](/filings/0001193125-25-265003.md) | [36.3 d](/filings/0001193125-26-067228.md) | [31.1](/filings/0001193125-26-206528.md) | [59.2 d](/filings/0001193125-26-332959.md) | [48.4 d](/filings/0001193125-25-265003.md) | [52.2 d](/filings/0001193125-26-067228.md) | [19.8](/filings/0001193125-26-206528.md) | [37.0 d](/filings/0001193125-26-332959.md) |
| Capital expenditure | $m | [5.4 d](/filings/0000950170-23-057180.md) | [11.6 d](/filings/0000950170-24-082104.md) | [4.8](/filings/0000950170-24-082111.md) | [6.2 d](/filings/0000950170-24-092740.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Dividends paid | $m | not reported | [0.0 d](/filings/0001193125-26-067228.md) | not reported | not reported | not reported | [0.0 d](/filings/0001193125-26-067228.md) | not reported | not reported | not reported | [0.0 d](/filings/0001193125-26-067228.md) | not reported | not reported |
| Share repurchases | $m | [0.0 d](/filings/0000950170-23-057180.md) | [0.0 d](/filings/0000950170-24-082104.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [34.2](/filings/0000950170-23-057180.md) | [34.5](/filings/0000950170-24-082111.md) | [34.5](/filings/0000950170-24-092740.md) | [32.1](/filings/0000950170-24-124037.md) | [32.3](/filings/0000950170-25-065770.md) | [32.3](/filings/0000950170-25-104162.md) | [41.5](/filings/0001193125-25-265003.md) | [69.5](/filings/0001193125-26-206528.md) | [69.1](/filings/0001193125-26-332959.md) | [69.3](/filings/0001193125-25-265003.md) | [68.9](/filings/0001193125-26-206528.md) | [69.5](/filings/0001193125-26-332959.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 69,935,827 at 2026-07-29, from the cover of the [10-Q filed 2026-08-04](/filings/0001193125-26-332959.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:31 ET. No prices; not investment advice.